Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1699978

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of discontinuing funding for T1DE pilot schemes on the health and well-being of patients living with type 1 diabetes with disordered eating.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20895
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England has provided funding for eight integrated care boards (ICBs) across the country to support the development and establishment of Type 1 Diabetes with Disordered Eating (T1DE) services in every National Health Service region. Funding has been provided on a pump prime basis, and the responsibility for the longer-term sustainable provision of care for these patients sits with the relevant integrated care system.</p><p>A nationally commissioned evaluation has shown the positive impact that the provision of T1DE services can have for patients, including reductions in HbA1c, which is linked to reduced rates of diabetes complications, and reduced rates of emergency admissions.</p><p>It’s the role of the ICBs to consider the health needs of their populations, in making decisions about the care that is provided. It is expected that ICB leads consider these evaluation findings alongside the risk to patient health and wellbeing of the discontinuation of service provision, as well as other local contextual factors in making decisions about the future provision of T1DE services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:53:21 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699979

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential implications for its policies of the cost-benefit analysis of the T1DE pilot schemes carried out by NHS England.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20896
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20897 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699980

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she (a) has made and (b) plans to make an assessment of the potential merits of funding options to ensure the sustainability of T1DE services beyond the pilot phase.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20897
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20896 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700035

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the rate of public satisfaction with the NHS was in (a) February 2024 or (b) the most recent month and year that data has been collected.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20898
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Data regarding the rate of public satisfaction with the National Health Service is publicly accessible, and is available at the following link:</p><p><a href="https://yougov.co.uk/topics/politics/explore/institution/NHS" target="_blank">https://yougov.co.uk/topics/politics/explore/institution/NHS</a></p><p>My Rt hon. Friend, the Secretary of State for Health and Social Care takes public perceptions of the NHS into account in her policy decisions. We have published recovery plans for elective services, urgent and emergency care, primary care and dental care, to improve access and performance of crucial NHS services.</p><p>Furthermore, we have made a great deal of progress in putting patients at the heart of care, through our recently announced programmes to expand choice, advanced care planning conversations, personal health budgets, and by providing more information to patients.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 20899 question first answered 18/04/2024 11:38:39 answering member 4492 label Biography information for Maria Caulfield
	tabling member	481 label Biography information for Sir George Howarth

1700036

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the potential implications for her policies of public satisfaction with the NHS.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20899
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Data regarding the rate of public satisfaction with the National Health Service is publicly accessible, and is available at the following link:</p><p><a href="https://yougov.co.uk/topics/politics/explore/institution/NHS" target="_blank">https://yougov.co.uk/topics/politics/explore/institution/NHS</a></p><p>My Rt hon. Friend, the Secretary of State for Health and Social Care takes public perceptions of the NHS into account in her policy decisions. We have published recovery plans for elective services, urgent and emergency care, primary care and dental care, to improve access and performance of crucial NHS services.</p><p>Furthermore, we have made a great deal of progress in putting patients at the heart of care, through our recently announced programmes to expand choice, advanced care planning conversations, personal health budgets, and by providing more information to patients.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 20898 question first answered 18/04/2024 11:38:39 answering member 4492 label Biography information for Maria Caulfield
	tabling member	481 label Biography information for Sir George Howarth

1700037

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Consultants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of NHS consultants carried out work in the private sector in the most recent financial year for which data is available.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20900
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 10:23:50 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688963

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Diseases: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with (a) NICE and (b) NHS England on encouraging the adoption of new treatments for (i) sickle cell disease and (ii) beta-thalassaemia.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13899
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>The Department regularly discusses a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), related to patient access to new treatments.</p><p> </p><p>The NICE appraises all new licensed medicines, and its recommendations are developed independently in line with its established methods and processes, on the basis of an assessment of the available evidence, and through extensive engagement with stakeholders. NHS England is legally required to fund treatments recommended in NICE technology appraisal guidance.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/02/2024 16:13:28 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688964

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with NICE on developing its methodologies to ensure future access to (a) innovative one-time treatments and (b) cell and genetic therapies.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13900
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE) and HM Treasury. The NICE is responsible for the methods and processes it uses to develop its recommendations, and concluded a comprehensive review of the methods and processes it uses for health technology evaluation, in January 2022. The NICE carried out the review through extensive engagement with stakeholders, including officials within the Department. The NICE introduced a number of changes that make its methods fairer, faster, more consistent, and appropriate to the evaluation of emerging new technologies, such as cell and gene therapies.</p><p>The NICE is monitoring the impact of the changes following the methods review and has committed to considering modular updates to its methods and processes in the future, including a planned update focussed on health inequalities in 2024. The NICE has been able to recommend several advanced therapeutic medicinal products, including one-off gene therapies, for National Health Service funding that are now available to NHS patients in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13901 13902 question first answered 21/02/2024 16:08:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688965

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the (a) National Institute for Health and Care Excellence (NICE) and (b) Chancellor of the Exchequer on the application of NICE's evaluation methods to support value assessment for one-off curative treatments for which health gains are accrued over time.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13901
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE) and HM Treasury. The NICE is responsible for the methods and processes it uses to develop its recommendations, and concluded a comprehensive review of the methods and processes it uses for health technology evaluation, in January 2022. The NICE carried out the review through extensive engagement with stakeholders, including officials within the Department. The NICE introduced a number of changes that make its methods fairer, faster, more consistent, and appropriate to the evaluation of emerging new technologies, such as cell and gene therapies.</p><p>The NICE is monitoring the impact of the changes following the methods review and has committed to considering modular updates to its methods and processes in the future, including a planned update focussed on health inequalities in 2024. The NICE has been able to recommend several advanced therapeutic medicinal products, including one-off gene therapies, for National Health Service funding that are now available to NHS patients in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13900 13902 question first answered 21/02/2024 16:08:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1688966

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the National Institute for Health and Care Excellence on updates in the way that it assesses medicines that reduce health inequalities.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	13902
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE) and HM Treasury. The NICE is responsible for the methods and processes it uses to develop its recommendations, and concluded a comprehensive review of the methods and processes it uses for health technology evaluation, in January 2022. The NICE carried out the review through extensive engagement with stakeholders, including officials within the Department. The NICE introduced a number of changes that make its methods fairer, faster, more consistent, and appropriate to the evaluation of emerging new technologies, such as cell and gene therapies.</p><p>The NICE is monitoring the impact of the changes following the methods review and has committed to considering modular updates to its methods and processes in the future, including a planned update focussed on health inequalities in 2024. The NICE has been able to recommend several advanced therapeutic medicinal products, including one-off gene therapies, for National Health Service funding that are now available to NHS patients in line with NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 13900 13901 question first answered 21/02/2024 16:08:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth